The European Medicines Agency is discussing whether Novo Nordisk should be granted approval to extend the EU indication of its blockbuster obesity drug Wegovy (semaglutide) to include its use for reducing the risk of major adverse cardiovascular events (MACEs), and also be awarded an extra year of market protection.
The company’s application for approval of the new indication and extended market protection is listed on this week’s draft...